Ampicillin Capsule 250mg Pharmaceutical

Name: Ampicillin Capsule 250mg Pharmaceutical
Brand: REYOUNG PHARMACEUTICAL CO., LTD.
SKU: 756672682

Shandong, ChinaREYOUNG PHARMACEUTICAL CO., LTD.

US$1.20

20,000 box

Sample price:US$2.00/box.Request sample

Product profile

Customization

Available

Application

Internal Medicine

Usage Mode

For oral administration

Model NO.

250mg

Suitable for

Elderly, Children, Adult

State

Solid

Shape

Capsules

Type

Organic Chemicals

Pharmaceutical Technology

Chemical Synthesis

Drug Reg./Approval No.

Lu20160062

Drug Ad Approval No.

Lu20160062

GMP Certificate

Yes

Transport Package

1000capsules/Tin. 10X10blisters/Box.

Specification

250mg

Trademark

Reyoung

Origin

China

HS Code

3004101190

Production Capacity

1 Minllion

Company profile

REYOUNG PHARMACEUTICAL CO., LTD.

Shandong, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 1997-01-01 CertifiedNearest Port: Qingdao PortAverage Response Time: ≤24h CertifiedTerms of Payment: LC, T/T, D/P

AI-Powered supplier vetting

SummaryReyoung Pharmaceutical Co., Ltd., established in 1966, is a leading pharmaceutical manufacturer based in Shandong, China. The company operates over 10 production lines, producing a variety of pharmaceutical products and exporting to South America, Africa, and Southeast Asia. It holds several certifications including ISO9001, ISO14001, and OHSAS18001. With a workforce of approximately 4950 employees, including 370 R&D engineers and 50 quality control staff, Reyoung Pharma demonstrates a strong emphasis on quality and innovation. The company has a significant annual production output and engages in international trade with countries like India and Bolivia.

Supplier typeReyoung Pharmaceutical Co., Ltd. is a combined manufacturing and distribution entity, operating as a limited company in Shandong, China.

CertificationsThe supplier holds ISO9001:2015, ISO14001:2015, and OHSAS18001:2007 certifications, indicating compliance with quality, environmental, and occupational health standards.

Financial creditReyoung Pharma has a registered capital of 78,560,000 RMB and owns assets worth over 1.5 billion USD, suggesting substantial financial stability.

R&D capabilityWith 370 R&D engineers, Reyoung Pharma shows a strong commitment to innovation in its pharmaceutical products.

Production capacityThe supplier operates above 10 production lines with an annual output exceeding US$100 million, demonstrating significant production capacity.

Client casesReyoung Pharma has engaged in trade transactions with companies like Sterile India Private Limited and Heredia Aracena Reny Evelin, illustrating international customer engagement.